Treatment Perspectives in Advanced Non-Small Cell Lung Cancer

Agelaki S. , Kouroussis C. , Mavroudis D. , Kalbasis K. , Souglakos J. , Reppa D. , Mixaki I. , Georgoulias V. : A phase I study of docetaxel (D) and oxaliplatin (L-OHP) as front-line treatment in metastatic breast cancer (MBC) and non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 19: 114a, 2000 (abstr. 443).

Baselga J. , Pfister D. , Cooper M.R. , Cohen R. , Burtness B. , Bos M. , D'Andrea G. , Seidman A. , Norton L. , Gunnett K. , Falcey J. , Anderson V. , Waksal H. , Mendelsohn J. : Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J. Clin. Oncol., 18: 904–914, 2000.

Bedikian A.Y. , Legha S.S. , Eton O. , Buzaid A.C. , Papadopoulos N. , Plager C. , McIntyre S. , Viallet J. : Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs, 10: 735–739, 1999.

Bonomi P. , Kim K. , Fairclough D. , Cella D. , Kugler J. , Rowinsky E. , Jiroutek M. , Johnson D. : Comparison of survival and quality of life in advanced non-small-cell lung cancer patients treated with two dose levels of paclitaxel combined with cisplatin versus etoposide with cisplatin: results of an Eastern Cooperative Oncology Group trial. J. Clin. Oncol., 18: 623–631, 2000.

Ciardiello F. , Caputo R. , Bianco R. , Damiano V. , Pomatico G. , De Placido S. , Bianco A.R. , Tortora G. : Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res., 6: 2053–2063, 2000.

Clarke S. , Boyer M. , Milward M. , Findlay M. , Ackland S. , Childs A. , Brew S. , Walcher Y. , Watt D. , Campbell L. : Multi-targeted antifolate MTA (LY231514): an active agent in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 17: 466a, 1998 (abstr. 1793).

Cobleigh M.A. , Vogel C.L. , Tripathy D. , Robert N.J. , Scholl S. , Fehrenbacher L. , Wolter J.M. , Paton V. , Shak S. , Lieberman G. , Slamon D.J. : Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol., 17: 2639–2648, 1999.

Cornelia P. , Frasci G. , Panza N. , Manzione L. , Lorusso V. , Di Rienzo G. , Cioffi R. , De Cataldis G. , Maiorino L. , Bilancia D. , Nicolella G. , Natale M. , Carpagnano F. , Pacilio C. , De Lena M. , Bianco A. , Cornelia G. : Cisplatin, gemcitabine and vinorelbine combination therapy in advanced non-small cell lung cancer: a phase II randomized study of the Southern Italy Cooperative Oncology Group. J. Clin. Ocnol., 17: 1526–1534, 1999.

Coussens L. , Yang-Feng T.L. , Liao Y.C. , Chen E. , Gray A. , McGrath J. , Seeburg P.H. , Libermann T.A. , Schlessinger J. , Francke U. : Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science, 230: 1123–1139, 1985.

Crinò L. , Mosconi A.M. , Scagliotti G. , Selvaggi G. , Novello S. , Rinaldi M. , Della Giulia M. , Gridelli C. , Rossi A. , Calandri C. , De Marinis F. , Noseda M. , Tonato M. : Gemcitabine as second-line treatment for advanced non-small cell lung cancer. A phase II trial. J. Clin. Oncol., 17: 2081–2085, 1999.

Cross M. , Dexter T.M. : Growth factors in the development, trasformation and tumorigenesis. Cell, 64: 271–280, 1991.

Cullen M.H. , Billingham L.J. , Woodroffe C.M. , Chetiyawardana A.D. , Gower N.H. , Joshi R. , Ferry D.R. , Rudd R.M. , Spiro S.G. , Cook J.E. , Trask C. , Bessell E. , Connolly C.K. , Tobias J. , Souhami R.L. : Mitomycin, ifosfamide, and cisplatin in unresectable non-small cell lung cancer: effects on survival and quality of life. J. Clin. Oncol., 17: 3188–3194, 1999.

De Cremoux H. , Bekradda M. , Monnet I. , Souliè P. , Saltiel S. , Misset J.L. , Fandi A. , Bensmaine M.A. , Cvitkovic E. : Preliminary report on oxaliplatin (L-OHP/navelbine (NVB) phase I/II multicentric trial in patients (pts) with advanced non-small celli lung cancer (NSCLC): an active combination. Proc. Am. Soc. Clin. Oncol., 17: 481a, 1998 (abstr. 1852).

DeVore R.F. , Fehrenbacher L. , Herbst R.S. , Langer C.J. , Kelly K. , Gaudreault J. , Holmgren E. , Novotny W.F. , Kabbinavar F. : A randomized phase II trial comparing rhumab VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) plus carboplatin/paclitaxel (CP) to CP alone in patients with stage IIIB/IV NSCLC. Proc. Am. Soc. Clin. Oncol., 19: 485a, 2000 (abstr. 1896).

Favaretto A. , Paccagnella A. , Oniga F. , Tumolo S. , Barbieri F. , Ceresoli G. , Gulisano M. , Schiavon S. : Paclitaxel and carboplatin with gemcitabine (PCG): a phase I-II trial in non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 19: 512a, 2000 (abstr. 2003).

Ferry D. , Hammond L. , Ranson M. , Kris M. , Miller V. , Murray P. , Tullo A. , Feyereislova A. , Averbuch S. , Rowinsky E. : Intermittent oral ZD1839 (Iressa), a novel epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), shows evidence of good tolerability and activity: final results from a phase I study. Proc. Am. Soc. Clin. Oncol., 19: 3a, 2000 (abstr. 5E).

Fontanini G. , Boldrini L. , Chine S. , Pisaturo F. , Basolo F. , Calcinai A. , Lucchi M. , Mussi A. , Angeletti C.A. , Bevilacqua G. : Expression of vascular endothelial growth factor mRNA in non-small-cell lung carcinomas. Br. J. Cancer, 79: 363–369, 1999.

Fossella F. , DeVore R. , Kerr R. , Crawford J. , Natale R. , Dunphy F. , Kalman L. , Gandara D. , Gamza F. , Hammershaimb L. , Kim Y. , Crist W. : Phase III trial of docetaxel 100 mg/m² or 75 mg/m² vs vinorelbine/ifosfamide for non-small cell lung cancer previously treated with platinum-based chemotherapy (PBC). Proc. Am. Soc. Clin. Oncol., 18: 460a, 1999 (abstr. 1776).

Frasci G. , Panza N. , Cornelia P. , Nicolella G.P. , Natale M. , Pacilio C. , Gravina A. , Caputi V. , Botti G. , Cornelia G. : Cisplatin, gemcitabine and vinorelbine in locally advanced or metastatic non-small cell lung cancer. A phase I study. Ann. Oncol., 8: 1045–1048, 1997.

Gatto C. , Rieppi M. , Borsotti P. , Innocenti S. , Ceruti R. , Drudis T. , Scanziani E. , Casazza A.M. , Taraboletti G. , Giavazzi R. : BAY 12-9566, a novel inhibitor of matrix metallo-proteinases with antiangiogenic activity. Clin. Cancer Res., 5: 3603–3607, 1999.

Giaccone G. , Smit E.F. , van Meerbeeck J.P. , Splinter T. , Golding R.P. , Pinedo H.M. , Laan D. , van Tinteren H. , Postmus P.E. : A phase I-II study of gemcitabine and paclitaxel in advanced non-small cell lung cancer patients. Ann. Oncol., 11: 109–112, 2000.

Gonzalez Baron M. , Garcia M.J. , Chacon J.I. , Ordonez A. , Madronal C. , Murias A. , Cruz M.A. , Castro J. , Feliu J. , Colmenarejo A. , Aguia J. : A phase II of gemcitabine, cisplatin, and vinorelbine in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 17: 469a, 1998 (abstr. 1802).

Grau C. , Overgaard J. : Effect of cancer chemotherapy on the hypoxic fraction of a solid tumor measured using a local tumor control assay. Radiother. Oncol., 13: 301–309, 1988.

Gridelli C. , Frontini L. , Perrone F. , Gallo C. , Gulisano M. , Cigolari S. , Castiglione F. , Robbiati S.F. , Gasparini G. , Ianniello G.P. , Farris A. , Locatelli M.C. , Felletti R. , Piazza E. : Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different doses. Br. J. Cancer, 83: 707–714, 2000.

ISTAT, Cause di morte, 1994. Roma, 1997.

Jarvis W.D. , Grant S. : Protein kinase C targeting in antineoplastic treatment strategies. Invest. New Drugs, 17: 227–240, 1999.

Karp D. , Silberman S. , Csudae R. , Wirth F. , Gaynes L. , Posner M. , Bubley G. , Koon H. , Bergman M. , Huang M. , Schnipper L.E. : Phase I dose escalation study of epidermal growth factor recptor (EGFR) tyrosine kinase (TK) inhibitor CP-358.774 in patients with advanced solid tumors. Proc. Am. Soc. Clin. Oncol., 18: 388a, 1999 (abstr. 1499).

Kelly K. , Crowley J. , Bunn P. , Livingston R.B. , Gandara D.R. : Southwest Oncology Group: a randomized phase III trial of paclitaxel plus carboplatin (PC) versus vinorelbine plus cispaltin (VC) in untreated advanced non-small cell lung cancer (NSCLC): a Southwest Oncology Group Trial. Proc. Am. Soc. Clin. Oncol., 18: 461a, 1999 (abstr. 1777).

Kelly K. , Prindiville S. , Bunn P.A. Jr. : A phase I trial of paclitaxel (P), carboplatin (C), and gemcitabine (G) in advanced non-small cell lung cancer: A University of Colorado Cancer Centre study. Proc. Am. Soc. Clin. Oncol., 17: 490a, 1998 (abstr. 1885).

Levin M. , Novetsky A. : A phase II study of docetaxel, vinorelbine G-CSF chemotherapy in patients with unresectable or metastatic non-small cell cancer of the lung. Proc. Am. Soc. Clin. Oncol., 18: 514a, 1999 (abstr. 1982).

Lorusso V. , Carpagnano F. , Frasci G. , Panza N. , Di Rienzo G. , Cisternino M.L. , Napoli G. , Orlando S. , Cinieri S. , Brunetti C. , Palazzo S. , De Lena M. : Phase I/II study of gemcitabine plus vinorelbine as first-line chemotherapy of non-small cell lung cancer. J. Clin. Oncol., 18: 405–411, 2000.

Mattson K. , Pawel J.V. , Manegold C. , Postmus P. , Clarke S. : MTA (Multitargeted Antifolate, LY231514) in NSCLC patients who failed previous platinum or non-platinum chemotherapy: a phase II trial. Proc. Am. Soc. Clin. Oncol., 18: 1892 (abstr.), 1999.

Miller V.A. , Krug L.M. , Ng K.K. , Pizzo B. , Perez W. , Heelan R.T. , Kris M.G. : Phase II trial of docetaxel and vinorelbine in patients with advanced non-small-cell lung cancer. J. Clin. Oncol., 18: 1346–1350, 2000.

Monnet I. , Brienza S. , Hugret F. , Voisin S. , Gastiaburu J. , Saltiel J.C. , Soulie P. , Armand J.P. , Cvitkovic E. , de Cremoux H. : Phase II study of oxaliplatin in poor-prognosis non-small cell lung cancer (NSCLC). ATTIT. Association pour le Traitement des Tumeurs Intra Thoraciques. Eur. J. Cancer, 34: 1124–1127, 1998.

Nelson A.R. , Fingleton B. , Rothenberg M.L. : Matrix metallo-proteinases: biologic activity and clinical implications. J. Clin. Oncol., 18: 1135–1149, 2000.

Non-small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials: Non-small Cell Lung Cancer Collaborative Group. BMJ, 311: 899–909, 1995.

O’ Rourke M. , Garfield D. , Ellis P. : Phase II trial of taxotere (T) and navelbine (N) as first-line therapy in patients with advanced non-small cell lung cancer. Proc. Am. Soc. Clin. Oncol., 18: 519a, 1999 (abstr. 1999).

Pectasides D. , Aspropotamitis A. , Halikia A. , Visvikis A. , Antoniou F. , Kalantaridou A. , Karvounis N. , Batzios S. , Athanassiou A. : Combination chemotherapy with carboplatin docetaxel and gemcitabine in advanced non-small cell lung cancer: a phase II study. Eur. J. Cancer, 35: 263, 1999 (suppl. 4, abstr. 1048).

Raymond E. , Chaney S.G. , Taamma A. , Cvitkovic E. : Oxaliplatin: a review of preclinical and clinical studies. Ann. Oncol., 9: 1053–1071, 1998.

Rowinsky E.K. , Humphrey R. , Hammond L.A. , Aylesworth C. , Smetzer L. , Hidalgo M. , Morrow M. , Smith L. , Garner A. , Sorensen J.M. , Von Hoff D.D. , Eckhardt S.G. : Phase I and pharmacologic study of the specific matrix metalloproteinase inhibitor BAY 12-9566 on a protracted oral daily dosing schedule in patients with solid malignancies. J. Clin. Oncol., 18: 178–186, 2000.

Rusch V. , Baselga J. , Cordon-Cardo C. , Orazem J. , Zaman M. , Hoda S. , McIntosh J. , Kurie J. , Dmitrovsky E. : Differential expression of the epidermal growth factors receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res., 53: 2379–2385, 1993.

Sandler A.B. , Nemunaitis J. , Dehnam C. , von Pawel J. , Cormier Y. , Gatzemeier U. , Mattson K. , Manegold C. , Palmer M.C. , Gregor A. , Nguyen B. , Niyikiza C. , Einhorn L.H. : Phase III trial of gemcitabine plus cisplatin versus cispaltin alone in patients with locally advanced or metastatic non-small cell lung cancer. J. Clin. Oncol., 18: 122–130. 2000.

Schiller J.H. , Harrington D. , Sandler A. , Belani C. , Langer C. , Krook J. , Johnson D.H. : A randomized phase III trial of four chemotherapy regimens in advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 19: la, 2000 (abstr. 2).

Schultz R.M. , Chen V.J. , Bewley J.R. , Roberts E.F. , Shih C. , Dempsey J.A. : Biological activity of the multitargeted antifolate, MTA (LY231514), in human cell lines with different resistance mechanisms to antifolate drugs. Sem. Oncol., 26(2 Suppl. 6): 68–73, 1999.

Senan S. , Rampling R. , Graham M.A. , Wilson P. , Robin H. Jr. , Eckardt N. , Lawson N. , McDonald A. , von Roemeling R. , Workman P. , Kaye S.B. : Phase I and pharmacokinetic study of tirapazamine (SR4233) administered every three weeks. Clin. Cancer Res., 3: 31–38, 1997.

Shephard P. , Ramlau R. , Mattson K. , Gressot L. , O’ Rourke M. , Vincent M. , Burkes R. , Levitan N. , Bergman B. , Kraszko P. , Baez L. , Lynch T. , Rudd R. , Berille J. , Kim Y. , Coughlin Y. , Gralla R. : Randomized study of taxotere (TAX) versus best supportive care (BSC) in non-small cell lung cancer patients previously treated with platinum-based chemotherapy. Proc. Am. Soc. Clin. Oncol., 18: 463a, 1999 (abstr. 1784).

Shepherd F.A. , Arnold A. , Neville A. , Cormier Y. , Davis M. , Wierzbicki R. , Dancey J. , Rusthoven J. , Fisher B. , Eisenhauer E. : Phase II study of MTA (Alimta) and cisplatin in patients with advanced non-small cell lung cancer (NSCLC). Proc. Am. Soc. Clin. Oncol., 19: 507a, 2000 (abstr. 1984).

Slamon D. , Leyland-Jones B. , Shak S. , Paton V. , Bajamonde A. , Fleming T. , Eiermann W. , Wolter J. , Baselga J. , Norton L. : Addition of herceptin (humanized anti-her2 antibody) to firts line chemotherapy for her2 overexpressing metastatic breast cancer (her2+/mbc) markedly increases anticancer activity: a randomized multinational controlled phase II trial. Proc. Am. Soc. Clin. Oncol., 17: 98a, 1998 (abstr. 377).

von Pawel J. , von Roemeling R. , Gatzemeier U. , Boyer M. , Elisson L.O. , Clark P. , Talbot D. , Rey A. , Butler T.W. , Hirsh V. , Olver I. , Bergman B. , Ayoub J. , Richardson G. , Dunlop D. , Arcenas A. , Vescio R. , Viallet J. , Treat J. : Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: a report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small cell lung tumors. J. Clin. Oncol., 18: 1351–1351, 2000.

Wojtowicz-Praga S. , Torri J. , Johnson M. , Steen V. , Marshall J. , Ness E. , Dickson R. , Sale M. , Rasmussen H.S. , Chiodo T.A. , Hawkins M.J. : Phase I trial of Marimastat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol., 16: 2150–2156, 1998.

Wozniak A.J. , Crowley J.J. , Balcerzak S.P. , Weiss G.R. , Spiridonidis C.H. , Baker L.H. , Albain K.S. , Kelly K. , Taylor S.A. , Gandara D.R. , Livingston R.B. : Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small cell lung cancer: a Southwest Oncology Group study. J. Clin. Oncol., 16: 2459–2465, 1998.

Wunderlich D. , Buechele T. , Zamoryn R. , Kegel T. , Mueller L.P. , Grothey A. , Schmoll H.J. , Graubner M. : Biweekly docetaxel (DOC), gemcitabine (GEM) and oxaliplatin (LOHP) in pretreated patients with solid tumors. Results of a phase I study. Proc. Am. Soc. Clin. Oncol., 19: 221a, 2000 (abstr. 862).

Yamamoto T. , Ikawa S. , Akiyama T. , Semba K. , Nomura N. , Miyajima N. , Saito T. , Toyoshima K. : Similarity of protein encoded by human c-erb-B-2 gene to epidermal growth factor receptor. Nature, 319: 230–234, 1986.

Zhu Z. , Witte L. : Inhibition of tumor growth and metastasis by targeting tumor-associated angiogenesis with antagonist to the receptors of vascular endothelial growth factor. Invest. New Drugs, 17: 195–212, 1999.